Noncomplication in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 6, Issue 2, 2001, Pages 164-168

  Gaston, Robert S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; ARTICLE; BEHAVIOR MODIFICATION; DRUG COST; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICARE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; RECIPIENT; TREATMENT OUTCOME; VERBAL COMMUNICATION;

EID: 0034956201     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200106000-00011     Document Type: Article

References (42)

1. Late renal allograft loss: Noncompliance masquerading as chronic rejection
2. Practical issues in medication compliance
3. Relation between medication compliance and medical outcomes
4. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
5. Assessing medication adherence by pill count and electronic monitoring in the AASK pilot study
6. Compliance with medication in the Helsinki Heart Study
7. Factors affecting compliance with cyclosporine in adult renal transplant patients
8. Nonadherence to immunosuppressive medications: A pilot survey of members of the Transplant Recipients International Organization
9. Compliance and noncompliance in patients with a functioning renal transplant: A multicenter study
10. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients
11. Causes of graft loss beyond two years in the cyclosporine era
12. A study of treatment compliance following kidney transplantation
13. Noncompliance in organ transplant recipients
14. The impact of an acute rejection episode on long-term renal allograft survival
15. Patients with a low income have reduced renal allograft survival
16. Medication compliance following renal transplantation: The natural history
17. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients
18. Increased morbidity and high variability of cyclosporine levels in pediatric heart transplant recipients
19. Racial disparities in renal transplant outcomes
20. Withdrawal of steroids after renal transplantation-clinical predictors of outcome
21. Prednisone withdrawal in kidney transplant recipients on CsA/MMF-a prospective, randomized study
22. Tapering or discontinuing cyclosporine for financial reasons-a single center experience
23. Solid organ transplantation: Are there predictors for posttransplant noncompliance? A literature overview
24. Compliance with cyclosporine in adolescent renal transplant recipients
25. Noncompliance in children and adolescents after renal transplantation
26. Psychosocial evaluation and prediction of compliance problems and morbidity after heart transplantation
27. Religious reasons for discontinuation of immuno-suppressive medications after renal transplant
28. The compliance of renal transplant recipients with advice about sun protection measures
29. Evaluation of a multivariate model predicting noncompliance with medication regimens among renal transplant patients
30. Payment for immunosuppression after organ transplantation
31. A medical anthropologist's view on posttransplant compliance: The underground economy of medical survival
32. Hypertension following renal transplantation
33. Hyperlipidemia in solid organ transplantation
34. Organ transplantation as a transformative experience: Anthropological insights into the restructuring of the self
35. Medicare beneficiaries management of capped prescription benefits
36. Methodological issues in transplant compliance research
37. Compliance declines between clinic visits
38. The evaluation of candidates for renal transplantation: The current practice of US transplant centers
39. Benefits of continued cyclosporine through an indigent drug program
40. Medicare's extended immunosuppression coverage improved graft survival